ITF Pharma, Inc. (“ITF”) has changed the company name to EDW Pharma, Inc. (“EDW”). The name change was effective November 1, 2023. EDW remains the parent company of both Womens Choice Pharmaceuticals, LLC and Edwards Pharmaceuticals, Inc. In addition, effective November 1, 2023, EDW moved the company’s corporate headquarters from Berwyn, PA to Paoli, PA. … Read more
Berwyn, Pa., Dec. 13, 2019 – EDW Pharma, a U.S.-based specialty pharmaceutical company and subsidiary of Italfarmaco, a privately-held European specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved its application to broaden the existing label for TIGLUTIK® (riluzole) oral suspension to include administration via percutaneous endoscopic gastrostomy (PEG) tubes for the treatment of amyotrophic lateral sclerosis (ALS).
EDW Pharma, a U.S.-based specialty pharmaceutical company committed to investing in and commercializing impactful medicines in therapeutic areas with unfulfilled needs, has united with The ALS Association to fight to defeat ALS.